KalVista Pharmaceuticals (KALV) Non-Current Debt (2015 - 2016)
KalVista Pharmaceuticals (KALV) reported Non-Current Debt of $2.7 million for Q1 2016, down 20.65% on a YoY basis from $3.4 million in Q2 2015, and down 14.36% sequentially from $3.2 million in Q4 2015.
KalVista Pharmaceuticals (KALV) Non-Current Debt (2015 - 2016) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 2 years of Non-Current Debt data on file, last reported at $2.7 million in Q1 2016.
- For the quarter ending Q1 2016, Non-Current Debt fell 20.65% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2016 stood at $2.7 million (down 20.65% YoY), and the FY2015 full-year result was $3.2 million, changed N/A from the prior year.
- Non-Current Debt eased to $2.7 million in Q1 2016, from $3.2 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $4.0 million in Q2 2015 to a low of $2.7 million in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 2.70 Mn |
| Dec 31, 2015 | 3.15 Mn |
| Sep 30, 2015 | 3.60 Mn |
| Jun 30, 2015 | 4.04 Mn |
| Mar 31, 2015 | 3.40 Mn |